Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 14/20 | 0.61 |
| ▸ | EGFR | P00533 | 16/20 | 0.60 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.51 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5266181 | 1.00 | ERBB2 (0.61) | ERBB2EGFRERBB3ERBB4GAK | |
| SCHEMBL4070061 | 0.90 | EGFR (0.72) | ERBB2EGFRERBB3ERBB4GAK | |
| SCHEMBL14208296 | 0.88 | EGFR (0.56) | ERBB2EGFRERBB3ERBB4GAK | |
| SCHEMBL4066817 | 0.86 | EGFR (0.52) | ERBB2EGFRERBB4GAK | |
| SCHEMBL4068899 | 0.86 | EGFR (0.52) | ERBB2EGFRERBB4GAK | |
| SCHEMBL4064958 | 0.82 | ERBB2 (0.62) | ERBB2EGFR | |
| SCHEMBL4066483 | 0.81 | EGFR (0.52) | ERBB2EGFRGAK | |
| SCHEMBL4064966 | 0.81 | EGFR (0.53) | ERBB2EGFRERBB4GAK | |
| SCHEMBL4069530 | 0.81 | EGFR (0.58) | ERBB2EGFRERBB4 | |
| SCHEMBL4064546 | 0.78 | EGFR (0.54) | ERBB2EGFRGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863792-B1 | ATP COMPETITIVE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-21 | — | — | EP | disclosed |
| US-7358256-B2 | ATP competitive kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358256-B2 | ATP competitive kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358256-B2 | ATP competitive kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1863792-A1 | ATP COMPETITIVE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006104971-A1 | ATP COMPETITIVE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060217369-A1 | Antiproliferative agents; tyrosine kinase inhibitors; anticancer; diseases associated with signal transduction pathways operating through growth factor receptors; 4-amino-1-((4-(3-methoxyphenylamino) quinazolin-5-yl)methyl)-N-methylpiperidine-3-carboxamide | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217369-A1 | Antiproliferative agents; tyrosine kinase inhibitors; anticancer; diseases associated with signal transduction pathways operating through growth factor receptors; 4-amino-1-((4-(3-methoxyphenylamino) quinazolin-5-yl)methyl)-N-methylpiperidine-3-carboxamide | ERBB2, ERBB4, EGFR | ERBB2 1/4885EGFR 3/4885ERBB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.